Respinor is developing an ultrasound sensor for continuous monitoring of the diaphragm, the main breathing muscle. Our technology has a broad range of potential benefits and represents a technology platform for applications in critical care and in respiratory medicine.
The novelty of the device lies in the usage of a small ultrasound transducer in a highly specialized probe design that can be fixed to the skin surface using a patented, disposable, adhesive solution. The device is easy to use and allows for continuous monitoring of diaphragm excursion and respiratory rate. Nineteen units of the clinical prototype have been manufactured and clinical testing has been ongoing since September 2016. Using these prototype units our clinical program continues with a set of observational studies throughout 2017. By the end of 2017, we will have developed a CE-marked product to be used in the H2020 funded randomized clinical trial starting in 2018.
Our first target application will be patients in the intensive care unit (ICU) under mechanical ventilation (MV), and more specifically for assessing the patient during the weaning process when the breathing tube is removed. There is currently a severe lack of accurate and cost-effective solutions to support the weaning process. Respinor aims to fill this gap by demonstrating and commercializing a cost-effective and user friendly ultrasound device that will effectively support the weaning process.